WSJ: Lilly banking on late-stage drugs

Share this article:

Eli Lilly CEO John Lechleiter says he's not ready to cut his firm's $5.3-billion R&D budget yet, but if the firm's late-stage pipeline doesn't pan out, that's exactly what he'll need to do.

Lilly is scheduled to report earnings Wednesday. In an interview with The Wall Street Journal, the CEO made no mention of another large-scale reorganization the likes of Merck's earlier this month.

The Indianapolis pharma spends 23% of revenue on R&D -- one of the highest R&D spending rates in pharma, according to the WSJ. It's risen 20% since 2009. 

The late-stage pipeline includes solanezumab for Alzheimer's, and three diabetes drugs: SGLT2 inhibitor empagliflozin, the dulaglutide GLP-1 and a Lantus-like long-acting form of insulin.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.